Semaglutide: what the human research actually shows
The real thing. The human evidence is the strongest of any peptide on this site. The problem with Semaglutide in 2026 is not whether it works, it is the gap between the approved-pharmacy version and the research-chemical version that the internet is flooded with.
Why I looked into this
Semaglutide is the only peptide on my list that the average reader’s primary care clinician has already heard of and probably already prescribed. It is also the peptide most aggressively mis-sold on the research-chemical internet, under the standard research-use-only labeling that the site spends most of its ink trying to demystify.
I wanted to walk through what the actual Phase 3 trials showed, what the FDA label actually warns about, and what changes about the source-safety calculation when the legitimate product is a prescription drug sitting behind a real pharmacy counter.
What Semaglutide actually is
Semaglutide is a synthetic long-acting agonist of the GLP-1 receptor. Natural GLP-1 is a short-lived incretin hormone released from the gut after eating. Semaglutide is engineered to bind the same receptor, survive in the bloodstream for days rather than minutes, and act on the same downstream pathways: insulin secretion in a glucose-dependent way, slowed gastric emptying, and reduced appetite signaling in the hypothalamus.
Ozempic and Wegovy are identical semaglutide molecules. The regulatory difference is the label and the maximum-approved dose. Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management in adults with obesity or with overweight plus at least one weight-related comorbidity. Rybelsus is a daily oral pill formulation approved for type 2 diabetes.
What the human research shows
Do published human trials exist?
Yes, more than for any other peptide on this site.
Semaglutide has been through multiple Phase 3 programs. The SUSTAIN program (type 2 diabetes), the STEP program (obesity), the PIONEER program (oral), and the SELECT cardiovascular outcomes trial together enrolled well over 17,000 patients in randomized placebo-controlled settings. The SELECT trial alone enrolled 17,604 patients and ran with a mean follow-up of nearly four years. Funding is largely industry (Novo Nordisk), which is worth naming plainly.
What evidence actually exists?
The most important trials to know:
- Wilding JPH et al., NEJM, 2021 (STEP 1). 1,961 adults with obesity or overweight plus comorbidity. 68 weeks, weekly semaglutide at the obesity-indicated high dose versus placebo, both arms with lifestyle intervention. Mean body weight change: minus 14.9 percent in semaglutide, minus 2.4 percent in placebo. Half the treatment arm lost at least 15 percent of body weight. Nausea 44 percent and diarrhea 31 percent in the treatment arm.
- Lincoff AM et al., NEJM, 2023 (SELECT). 17,604 patients aged 45+ with established cardiovascular disease and obesity but no diabetes. Primary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke occurred in 6.5 percent of the semaglutide arm versus 8.0 percent of placebo. Hazard ratio 0.80 (95 percent CI 0.72 to 0.90, p less than 0.001).
- The SUSTAIN program (SUSTAIN 1 through 10): multiple type 2 diabetes trials comparing weekly semaglutide against placebo and against active comparators, consistently showing HbA1c reduction and modest weight loss.
- The PIONEER program: oral semaglutide trials for type 2 diabetes.
What the research does not show
The research does NOT show:
- That weight loss is permanent after stopping. The STEP 4 trial specifically tested continued versus withdrawn semaglutide at week 20. The withdrawal arm regained most of the lost weight.
- That Semaglutide is a cosmetic weight-loss product. The Phase 3 trials were run in populations with real metabolic disease. The evidence base for healthy-weight adults using semaglutide for minor vanity targets is essentially zero.
- Long-term (10+ year) safety data in a broad real-world population.
- Equivalent benefit in people who get their product from research-chemical suppliers instead of pharmacies. Research-use-only vials have no identity or purity guarantee.
- Benefit without the side-effect profile. Gastrointestinal effects are common, sometimes severe, and are the primary reason people discontinue.
Known safety signals in humans
The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent findings. The label also carries warnings for pancreatitis, acute gallbladder disease, acute kidney injury (mostly driven by dehydration from GI symptoms), diabetic retinopathy complications in type 2 diabetes patients, and hypoglycemia when combined with insulin or sulfonylureas.
In September 2023, FDA updated the Ozempic label to include ileus after postmarketing reports. Both Ozempic and Wegovy labels state the products are not recommended in patients with severe gastroparesis. Gastrointestinal adverse events (nausea, diarrhea, constipation, vomiting) are the most common cause of discontinuation across the Phase 3 programs.
FDA and legal status in the US
Semaglutide is the peptide on this list with the clearest legal pathway. It is available through licensed pharmacies with a valid prescription, at the approved dose titration and for the approved indications. The complication is the gray market. During the 2022-2024 supply shortage, compounded semaglutide proliferated, often outside a rigorous 503A physician-supervised framework. FDA has since taken steps to narrow compounding as the brand-name supply has recovered.
Research-use-only vials marketed on the open internet are a separate, older, and worse problem. These are not pharmacy products, not compounded under a 503A framework, and do not carry identity or purity assurances. Using them for human purposes is not a legal use-pathway and is not what the FDA label covers.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for Semaglutide specifically
Semaglutide is the peptide on this list where source-safety is most important and most ignored. Every Phase 3 trial result cited above applies to GMP-manufactured Novo Nordisk semaglutide dispensed under pharmacist oversight. Those results do not transfer automatically to research-use-only vials with no identity testing, no sterility assurance, and no supply-chain accountability.
The gray-market semaglutide market exploded during the 2022-2024 shortage. Analytical surveys of research-use-only semaglutide have documented wide variation in purity and, in some cases, the wrong peptide entirely. If you are paying pharmacy prices for pharmacy-grade semaglutide, this section is for context. If you are considering saving money via a research-use-only vial, the efficacy and safety profile from the Phase 3 record does not apply to your vial.
Cost reality
Brand-name Wegovy list price in the US runs several hundred to well over a thousand dollars per month without insurance coverage. Ozempic similar. Compounded semaglutide during the shortage period typically ran in the low hundreds monthly. Research-use-only vials sell for a small fraction of either, which is exactly the economic gradient that makes source safety difficult.
Cheaper is not safer. Cheaper is very often a different product than the label claims.
Questions worth asking any source
- Is this product dispensed from a licensed pharmacy against a valid prescription from a licensed clinician?
- If compounded, is the pharmacy a licensed 503A compounder (patient-specific) or 503B (outsourcing facility), and does current law permit compounded semaglutide given the shortage-list status?
- Does the product carry a manufacturer lot number traceable to a GMP facility, not an in-house research-use-only lot?
- Is there a certificate of analysis from an independent laboratory, not the seller’s own?
- Is the full FDA prescribing information available with this product, or is it labeled research use only?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used Semaglutide. If I had the clinical indication the Phase 3 trials were run in, I would take it seriously as a real tool with real evidence. It is genuinely the strongest human-trial result on this site, and the cardiovascular outcomes signal in SELECT is not a small deal. Nothing else on my list comes close.
What I do not take seriously is the cosmetic-use framing that has attached itself to semaglutide since the Wegovy approval. The Phase 3 trials studied people with real metabolic disease. The side-effect profile is not minor. Gastrointestinal symptoms, gallbladder complications, and the ileus signal that showed up postmarketing are not priced into the casual social-media framing of semaglutide as a low-stakes lifestyle peptide.
The research-chemical version is a different conversation entirely. Those vials are not the thing that the STEP and SELECT trials studied. The efficacy and safety evidence that justifies the legitimate version does not automatically apply to a vial with no identity verification. Readers who understand that distinction are already thinking about this correctly. Readers who do not should read the source-safety section above with extra care.
For someone curious, read the STEP 1 paper and the SELECT paper. They are genuinely interesting even if you never intend to use semaglutide. For someone considering it, the pharmacy pathway with a real clinician is the only pathway that matches the evidence base. For someone already using it, the side-effect monitoring conversation matters more at month six than it did at month one.
Questions to ask your doctor
If you are considering Semaglutide, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- Based on my labs, BMI, and medical history, do I actually meet the indication the Phase 3 trials were run in, or am I thinking about this for a lifestyle reason the evidence base does not cover?
- How do you plan to monitor my gallbladder, pancreatic, and thyroid status over the first year, given the boxed warnings and postmarketing signals?
- If I develop significant nausea, vomiting, or abdominal pain, at what point should I stop and contact you, and when should I go directly to an emergency department?
- If cost is the concern, what insurance or manufacturer programs are realistic options, and what is your view on compounded versus brand-name given where the shortage list stands?
- What is the plan for tapering or stopping once I have reached my goal? I have read that weight tends to regain after discontinuation.
- Are there any current medications, including oral contraceptives or absorbable drugs, whose timing we need to adjust because of semaglutide’s effect on gastric emptying?
What to do next
Read STEP 1 and SELECT
Wilding 2021 NEJM and Lincoff 2023 NEJM are the two papers that set the modern baseline. Both are free to read in abstract form on PubMed.
Open the primer →Go to a real clinician
This is a peptide where the pharmacy pathway is straightforward. Bring the visit-prep packet to a primary care clinician and have the insurance conversation out loud.
Get the packet →Pharmacy, not research chemical
The Phase 3 evidence applies to pharmacy-dispensed semaglutide. It does not automatically apply to research-use-only vials. If you are using it, use the real version.
Open the checklist →Sources
- Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384:989-1002. Industry funded (Novo Nordisk). PMID 33567185.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes” (SELECT). New England Journal of Medicine. 2023;389:2221-2232. Industry funded (Novo Nordisk). PMID 37952131.
- Rubino DM, Greenway FL, Khalid U, et al. STEP 4 extension/withdrawal trial. JAMA. 2021. Industry funded.
- FDA Prescribing Information, Wegovy (semaglutide injection). Wegovy label (2024).
- FDA Prescribing Information, Ozempic (semaglutide injection). Ozempic label (2023).
- FDA MedWatch and postmarketing safety reporting; September 2023 label update on ileus and gastroparesis.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Tirzepatide
The dual-agonist that followed Semaglutide. Stronger weight-loss numbers in SURMOUNT. Read alongside to see how the GLP-1 class is evolving.
Retatrutide
The triple-agonist in Phase 2/3 that looks like the next step beyond Tirzepatide. My honest take includes a personal one-month experience.
AOD-9604
The opposite of Semaglutide on the evidence scale. A fat-loss fragment whose Phase 2 trials failed for the fat-loss endpoint, now sold as a peptide anyway.